Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians
Authors:
Open Access
- 15 June 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 9 (7) , ofac287
Abstract
Mycobacterium chimaera, a member of the Mycobacterium avium complex, can cause infections in individuals after open heart surgery due to contaminated heater-cooler units. The diagnosis can be challenging, as the incubation period can be quite variable, and symptoms are nonspecific. In addition to aggressive surgical management, combination pharmacologic therapy is the cornerstone of therapy, which should consist of a macrolide, a rifamycin, ethambutol, and amikacin. Multiple second-line agents may be utilized in the setting of intolerances or toxicities. In vitro susceptibility of these agents is similar to activity against other species in the Mycobacterium avium complex. Drug–drug interactions are frequently encountered, as many individuals have chronic medical comorbidities and are prescribed medications that interact with the first-line agents used to treat M. chimaera. Recognition of these drug–drug interactions and appropriate management are essential for optimizing treatment outcomes.Keywords
This publication has 150 references indexed in Scilit:
- In Vitro Synergy between Clofazimine and Amikacin in Treatment of Nontuberculous Mycobacterial DiseaseAntimicrobial Agents and Chemotherapy, 2012
- Eradication of bacterial persisters with antibiotic-generated hydroxyl radicalsProceedings of the National Academy of Sciences, 2012
- Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug ResistanceAntimicrobial Agents and Chemotherapy, 2012
- Pharmacokinetics and Pharmacodynamics of TMC207 and Its N -Desmethyl Metabolite in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Mycobacterium chimaera pulmonary infection complicating cystic fibrosis: a case reportJournal of Medical Case Reports, 2011
- Probing the Interaction of the Diarylquinoline TMC207 with Its Target Mycobacterial ATP SynthasePLOS ONE, 2011
- Occurrence and Clinical Relevance of Mycobacterium chimaera sp. nov., GermanyEmerging Infectious Diseases, 2008
- In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase InhibitorAntimicrobial Agents and Chemotherapy, 2007
- Genetic Basis for Natural and Acquired Resistance to the Diarylquinoline R207910 in MycobacteriaAntimicrobial Agents and Chemotherapy, 2006
- Pharmacokinetic Drug Interactions of MacrolidesClinical Pharmacokinetics, 1992